3 Essential Pharmaceuticals & Life Sciences Stories for Health Executives
Welcome to today's curated press review from Press Monitor, your source for Canadian print media monitoring on pharmaceuticals and life sciences. Stay ahead with these three essential stories.
1. University of Toronto Launches Heart Study for Older Adults
Toronto Star reports that the University of Toronto Research Ethics Board has approved a research study on heart health. The study is seeking participants aged 45 and older who have heart disease, take statin medication for cholesterol, and have internet access.
Why it matters: This research could reshape cardiovascular care for aging Canadians.
Key detail: The University of Toronto Research Ethics Board has approved a study seeking participants aged 45+ with heart disease on statins, with internet access required.
Source: Toronto Star.
Next step: Eligible individuals can contact U of T for enrollment details.
2. Valeo Pharma Retirement Plan Terminated – Claims Deadline Nears
Selon Le Journal de Montreal, le régime de retraite Pension Plan for Certain Employees of Valeo Pharma Inc. Formerly Employed by Baralex Inc. a été mis fin à la date du 3 décembre 2024. Les employés sans relevé de droits qui pensent avoir des droits sont invités à faire valoir leurs droits avant le 26 septembre 2026 auprès de l'administrateur provisoire. Retraite Québec propose aux retraités de faire administrer leurs rentes. Pour plus d'informations, consultez votre relevé de droits.
Why it matters: Former employees must act before the September 26, 2026 deadline to secure pension rights.
Key detail: The Pension Plan for Certain Employees of Valeo Pharma Inc. ended December 3, 2024; Retraite Québec is overseeing administration.
Source: Le Journal de Montreal.
Next step: Affected workers should check their benefit statements and submit claims promptly.
3. Fentanyl Drives BC Drug Death Increase in June
British Columbia reports increased drug-related fatalities in June 2026, with 138 deaths rising from 110 in May but remaining below the 2023 peak of 204. The B.C. Coroners Service attributes most cases to fluorofentanyl, detected in 67% of June deaths, while regional data shows Vancouver and Victoria facing disproportionate losses.
Why it matters: The opioid crisis continues to escalate, with fluorofentanyl detected in 67% of June fatalities.
Key detail: BC reported 138 deaths in June 2026, up from 110 in May, though below the 2023 peak of 204.
Source: Times Colonist.
Next step: Public health officials urge harm reduction and increased access to naloxone.
Stay informed with Press Monitor's daily print media tracking. What developments in pharma and life sciences are you watching?
